Viridian Therapeutics Plans Concurrent Public Offerings of Convertible Senior Notes Due 2032, Common Shares, and Series B Non-Voting Convertible Preferred Stock Viridian Therapeutics (Nasdaq: VRDN), a clinical-stage biopharmaceutical company focused on developing innovative therapies for autoimmune and rare diseases, has…
RestorixHealth Marks Hyperbaric Awareness Month with Nationwide Celebration RestorixHealth, a leading provider of wound care and hyperbaric center management services across the United States, has announced its participation in recognizing Hyperbaric Awareness Month this May. The annual observance, launched in…
Merck Finalizes Acquisition of Terns Pharmaceuticals, Strengthening Its Portfolio Merck & Co.—known as MSD outside the United States and Canada—has officially completed its acquisition of Terns Pharmaceuticals, marking a significant expansion of its oncology pipeline and reinforcing its long-term strategy…
First-in-Human Study of 50 Patients Shows Neptune Medical’s Triton Robotic Endoscopy System Achieves Zero Adverse Events and 100% Cecal Intubation in Colonoscopy Neptune Medical has reported encouraging results from its first-in-human clinical evaluation of the Triton Robotic Endoscopy System, marking…
Alnylam Pharmaceuticals to Showcase New Analyses at Heart Failure 2026 Highlighting the Consistent Clinical Profile of Vutrisiran in ATTR-CM Alnylam Pharmaceuticals (Nasdaq: ALNY) has announced that it will present a comprehensive set of new data analyses for vutrisiran in patients…
Rejoni Names John Nealon as Chief Executive Officer to Lead Its Women’s Health MedTech Strategy Rejoni Inc., a privately held clinical-stage biotechnology company focused on advancing uterine health through innovative biomaterial therapies, has announced the appointment of John Nealon as…
Assertio Enters into Revised and Restated Merger Agreement with Garda Therapeutics Assertio Holdings has announced a significant update to its pending acquisition by Garda Therapeutics, revealing that the two companies have entered into an amended and restated merger agreement as…
Ironwood Presents Survey Data at DDW 2026 Highlighting Urgent Need for Treatments Addressing the Multifaceted Burden of Total Parenteral Nutrition in Short Bowel Syndrome Ironwood Pharmaceuticals, a biotechnology company focused on developing and commercializing therapies for gastrointestinal (GI) and rare…
Incyte Secures FDA Approval for Jakafi XR™ (ruxolitinib) Extended-Release Tablets Across Multiple Hematologic Indications Incyte has announced that the U.S. Food and Drug Administration (FDA) has approved Jakafi XR™ (ruxolitinib) extended-release tablets, introducing a new once-daily treatment option for patients…
E-Scopics Secures FDA Clearance for Enhanced Hepatoscope® Featuring Advanced Elastography and Expanded Liver Disease Management Capabilities, to Be Showcased at DDW 2026 E-Scopics has announced a major advancement in its point-of-care ultrasound technology with new U.S. regulatory clearance for enhanced…
Arrowhead Pharmaceuticals Secures TGA Approval for REDEMPLO® (plozasiran) in Australia, Broadening Access for Patients with Familial Chylomicronemia Syndrome (FCS) Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) has announced a significant regulatory milestone with the approval of REDEMPLO by Australia’s Therapeutic Goods Administration…
Acadia Pharmaceuticals Plans Year-End Retirement of R&D Chief Elizabeth H.Z. Thompson After Distinguished Career Acadia Pharmaceuticals Inc. has announced that Elizabeth H.Z. Thompson, Ph.D., its Head of Research and Development, plans to retire from her role for personal reasons. The…